Diabetes and Hypertension

  • Samy I. McFarlane
  • Amal F. Farag
  • David Gardner
  • James R. Sowers
Part of the Contemporary Cardiology book series (CONCARD)


Diabetes is a major public health problem that is rapidly approaching epidemic proportions in the United States and worldwide (1, 2, 3). In the United States, more han 17 million persons currently have diabetes, a number that is expected to rise to 29 million by the year 2050 with a prevalence of 7.2% (4). Furthermore, the economic burden of diabetes to the US economy is monumental. In the year 2002, diabetes cost the United States an estimated $ 132 billion in medical expenditure and lost productivity (3). Cardiovascular disease (CVD) is by far the leading cause of death in people with diabetes accounting for up to 80% of mortality in this patient population (5, 6, 7, 8).


Metabolic Syndrome United Kingdom Prospective Diabetes Study Prevent Heart Attack Trial Myosin Phosphatase Cardiometabolic Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195–1200.PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States 2000. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention, 2002.Google Scholar
  3. 3.
    American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care 2003;26:917–932.Google Scholar
  4. 4.
    Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936–1940.PubMedGoogle Scholar
  5. 5.
    McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713–718.PubMedGoogle Scholar
  6. 6.
    Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134–1146.PubMedGoogle Scholar
  7. 7.
    Blendea MC, McFarlane SI, Isenovic ER, Gick G, Sowers JR. Heart disease in diabetic patients. Curr Diab Rep 2003;3:223–229.PubMedGoogle Scholar
  8. 8.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234.PubMedGoogle Scholar
  9. 9.
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053–1059.PubMedGoogle Scholar
  10. 10.
    Gress TW, Nieto J, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905–912.PubMedGoogle Scholar
  11. 11.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356–359.PubMedGoogle Scholar
  12. 12.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106(25):3143–3421.Google Scholar
  13. 13.
    Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541–1545.PubMedGoogle Scholar
  14. 14.
    Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003;108:1552–1553.PubMedGoogle Scholar
  15. 15.
    Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–1214.PubMedGoogle Scholar
  16. 16.
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689.PubMedGoogle Scholar
  17. 17.
    Alberti KG, Zimmet PZ.. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15(7):539–553.PubMedGoogle Scholar
  18. 18.
    Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996;45:1585–1593.PubMedGoogle Scholar
  19. 19.
    Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994;24:793–801.PubMedGoogle Scholar
  20. 20.
    Nakano S, Kitazawa M, Tsuda S, et al. INS resistance is associated with reduced nocturnal falls of blood pressure in normotensive, nonobese type 2 diabetic subjects. Clin Exp Hypertens 2002;24:65–73.PubMedGoogle Scholar
  21. 21.
    Nielsen FS, Hansen HP, Jacobsen P, et al. Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. Diabet Med 1999;16:555–562.PubMedGoogle Scholar
  22. 22.
    Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002;20:2183–2189.PubMedGoogle Scholar
  23. 23.
    White WB. A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996;9:29S–33S.PubMedGoogle Scholar
  24. 24.
    Semplicini A, Ceolotto G, Massimino M, et al. Interactions between INS and sodium homeostasis in essential hypertension. Am J Med Sci 1994;307(Suppl 1):S43–S46.PubMedGoogle Scholar
  25. 25.
    Weinberger MH. Salt sensitive human hypertension. Endocr Res 1991;17:43–51.PubMedGoogle Scholar
  26. 26.
    Luft FC, Miller JZ, Grim CE, et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension 1991;17:I102–I108.PubMedGoogle Scholar
  27. 27.
    Arun CS, Stoddart J, Mackin P, MacLeod JM, New JP, Marshall SM. Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care 2003;26:2144–2149.PubMedGoogle Scholar
  28. 28.
    Mitchell TH, Nolan B, Henry M, Cronin C, Baker H, Greely G. Microalbuminuria in patients with non-INS-dependent diabetes mellitus relates to nocturnal systolic blood pressure. Am J Med 1997;102:531–535.PubMedGoogle Scholar
  29. 29.
    Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45–66.PubMedGoogle Scholar
  30. 30.
    Tagle R, Acevedo M, Vidt DG. Microalbuminuria: is it a valid predictor of cardiovascular risk? Cleve Clin J Med 2003;70:255–261.PubMedGoogle Scholar
  31. 31.
    McFarlane SI, Farag A, Sowers J. Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovasc Drug Rev 2003;21:105–118.PubMedGoogle Scholar
  32. 32.
    Streeten DH, Anderson GH, Jr. The role of delayed orthostatic hypotension in the pathogenesis of chronic fatigue. Clin Auton Res 1998;8:119–124.PubMedGoogle Scholar
  33. 33.
    Streeten DH, Auchincloss JH Jr, Anderson GH, Jr., Richardson RL, Thomas FD, Miller JW. Orthostatic hypertension. Pathogenetic studies. Hypertension 1985;7:196–203.PubMedGoogle Scholar
  34. 34.
    Jacob G, Costa F, Biaggioni I. Spectrum of autonomic cardiovascular neuropathy in diabetes. Diabetes Care 2003;26:2174–2180.PubMedGoogle Scholar
  35. 35.
    Streeten DH. Pathogenesis of hyperadrenergic orthostatic hypotension. Evidence of disordered venous innervation exclusively in the lower limbs. J Clin Invest 1990;86:1582–588.PubMedGoogle Scholar
  36. 36.
    Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000;342(13):969–970.PubMedGoogle Scholar
  37. 37.
    Hypertension in Diabetes Study(HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11(3):309–317.Google Scholar
  38. 38.
    Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41(6):736–741.PubMedGoogle Scholar
  39. 39.
    Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (INS-dependent) diabetes mellitus. Diabetologia 1987;30(8):610–617.PubMedGoogle Scholar
  40. 40.
    Sowers JR, Sowers PS, Peuler JD. Role of INS resistance and hyperINSemia in development of hypertension and atherosclerosis. J Lab Clin Med 1994;123(5):647–652.PubMedGoogle Scholar
  41. 41.
    Sowers JR. Effects of INS and IGF-I on vascular smooth muscle glucose and cation metabolism. Diabetes 1996;45(Suppl 3):S47–S51.PubMedGoogle Scholar
  42. 42.
    Sechi LA, Melis A, Tedde R. INS hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism 1992;41:1261–1266.PubMedGoogle Scholar
  43. 43.
    Frohlich ED. INS and INS resistance: impact on blood pressure and cardiovascular disease. Medical Clinics N Am 2004;88:63–82.Google Scholar
  44. 44.
    Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. INS-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of INS to increase nitric oxide release. J Clin Invest 1994;94(3):1172–1179.PubMedGoogle Scholar
  45. 45.
    Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/INS resistance is associated with endothelial dysfunction. Implications for the syndrome of INS resistance. J Clin Invest 1996;97(11):2601–2610.PubMedGoogle Scholar
  46. 46.
    Sowers JR. Obesity and cardiovascular disease. Clin Chem 1998;44(8 Pt 2):1821–1825.PubMedGoogle Scholar
  47. 47.
    Sowers JR. Obesity as a cardiovascular risk factor. Am J Medicine 2003;115(8A):375–415.Google Scholar
  48. 48.
    El-Atat F, Aneja A, McFarlane S, Sowers JR. Obesity and hypertension. Endocrinol Metab Clin N Amer 2003;32:823–854.Google Scholar
  49. 49.
    Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989;83(4):1168–1173.PubMedGoogle Scholar
  50. 50.
    Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51(6):1699–1707.PubMedGoogle Scholar
  51. 51.
    Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001;14(6 Pt 2):103S–115S.PubMedGoogle Scholar
  52. 52.
    Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with INS resistance and hyperINSemia. J Clin Endocrinol Metab 2001;86(5):1930–1935.PubMedGoogle Scholar
  53. 53.
    Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107(5):671–674.PubMedGoogle Scholar
  54. 54.
    Shuldiner AR, Yang R, Gong DW. Resistin, obesity and INS resistance—the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001;345(18):1345.PubMedGoogle Scholar
  55. 55.
    Sowers JR, Ferdinand KC, Bakris GL, Douglas JG. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med 2002;112(4):24–26.PubMedGoogle Scholar
  56. 56.
    Sowers JR. Diabetic nephropathy and concomitant hypertension: a review of recent ADA recommendations. Am J Clin Proc 2002;3:27–33.Google Scholar
  57. 57.
    LeRoith D. INS-like growth factors. N Engl J Med 1998;336:633–640.Google Scholar
  58. 58.
    Sowers J. INS and INS-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997;29:691–699.PubMedGoogle Scholar
  59. 59.
    Standley PR, Zhang F, Sowers JR. IGF-1 regulation of Na+-K+-ATPase in rat arterial smooth muscle. Am J Physiol 1997;273:E113–E121.PubMedGoogle Scholar
  60. 60.
    Standley PR, Obards TJ, Martina CL. Cyclic stretch regulates autocrine IGF-1 in vascular smooth muscle cells: implications in vascular hyperplasia. Am J Physiol 1999;276:E697–E705.PubMedGoogle Scholar
  61. 61.
    Hayashi K, Saga H, Chimori Y, et al. Differentiated phenotype of smooth muscle cells depends on signaling pathways through INS-like growth factor and phosphatidylinositol 3-kinase. J Biol Chem 1998;273:28860–28867.PubMedGoogle Scholar
  62. 62.
    Sowers J. Effects of INS and IGF-1 on vascular smooth muscle glucose and cation metabolism. Diabetes 1996;45:S47–S51.PubMedGoogle Scholar
  63. 63.
    Walsh MF, Barazi M, Sowers JR. IGF-1 diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996;137:1798–1803.PubMedGoogle Scholar
  64. 64.
    Muniyappa R, Walsh MF, Sowers JR. INS-like growth f actor-1 increases vascular smooth muscle nitric oxide production. Life Sciences 1997;61:925–933.PubMedGoogle Scholar
  65. 65.
    Wu HY, Jeng YY, Hsueh WA. Endothelial-dependent vascular effects of INS and INS-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes 1994;43:1027–1032.PubMedGoogle Scholar
  66. 66.
    Zeng G, Nystrom FH, Quon, MJ. Roles for INS receptor, PI3-kinase and Akt in INS-signaling pathways related to production of nitric oxide in human vascular endothelialc cells. Circulation 2000;101:1539–1545.PubMedGoogle Scholar
  67. 67.
    Sowers J. INS and INS-like growth factor-1 effects on CA2+ and nitric oxide in diabetes. In: Levin ER, Nadler JL, (eds.). Endocrinology of cardiovascular function. Kluwer Academic Publishers, Boston, Massachusetts, 1998, pp. 139–158.Google Scholar
  68. 68.
    Hasdai D, Rizza R, Holmes D, et al. INS and INS-like growth factor-1 cause coronary vasorelaxation in vitro. Hypertension 1998;32:228–234.PubMedGoogle Scholar
  69. 69.
    Li D, Sweeney G, Wang Q, Klip A. Participation of PI3K and atypical PKC in Na+,K+-pump stimulation by IGF-1 in VSMC. Am J Physiol 1999;276:H2109–H2116.PubMedGoogle Scholar
  70. 70.
    Inishi Y, Katoh T, Okada T. Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats. Kidney Int 1997;52:165–170.PubMedGoogle Scholar
  71. 71.
    Isenovic ER, Muniyappa R, Sowers JR. Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity. BBRC 2001;285:954–958.PubMedGoogle Scholar
  72. 72.
    Walsh MF, Ali S. Sowers JR. Vascular INS/INS-like growth factor-1 resistance in female obese Zucker rats. Metabolism 2001;50:607–612.PubMedGoogle Scholar
  73. 73.
    Vecchione C, Colella S, Fratta L, et al. Impaired INS-like growth factor-1 vasorelaxant effects in hypertension. Hypertension 2001;37:1480–1485.PubMedGoogle Scholar
  74. 74.
    Isenovic ER, Jacobs DB, Kedees MH, et al. Angiotensin II regulation of the Na+ pump involves the phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways in vascular smooth muscle cells. Endocrinology 2004;145(3):1151–1160.PubMedGoogle Scholar
  75. 75.
    Sowers JR. INS resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597–1602.PubMedGoogle Scholar
  76. 76.
    Zeng G, Quon MJ. INS-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;15;98:894–898.Google Scholar
  77. 77.
    Tirupattur PR, Ram JL, Standley PR, Sowers JR. Regulation of Na+,K(+)-ATPase gene expression by INS in vascular smooth muscle cells. Am J Hypertens 1993;6:626–629.PubMedGoogle Scholar
  78. 78.
    Sowers JR, Draznin B. INS, cation metabolism and INS resistance. J Basic Clin Physiol Pharmacol 1998;9:223–233.PubMedGoogle Scholar
  79. 79.
    Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003;16:41S–45S.PubMedGoogle Scholar
  80. 80.
    Zemel MB, Peuler JD, Sowers JR. Hypertension in INS-resistant Zucker obese rats is independent of neural support. Am J Physiol 1992;262:E368–E371.PubMedGoogle Scholar
  81. 81.
    Henriksen EJ, Jacob S, Kinnick T, et al. Selective angiotensin II receptor antagonism reduces INS resistance in obese Zucker rats. Hypertension 2001;38:884–890.PubMedGoogle Scholar
  82. 82.
    Ouchi Y, Han S, Kim S, et al Augmented contractile function and abnormal Ca2+ handling in the aorta of Zucker obese rats with INS resistance. Diabetes 1996;45:S55–S58.PubMedGoogle Scholar
  83. 83.
    Kolter T, Uphues I, Eckel J. Molecular analysis of INS-resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 1997;36:E59–E67.Google Scholar
  84. 84.
    Ren J, Walsh MF, Sowers JR. Altered inotrophic response to IGF-1 in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol 1998;275:H823–H830.PubMedGoogle Scholar
  85. 85.
    Leri A, Liu Y, Wang X, Kajstura J, et al. Overexpression of INS-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. Circ Res 1999;84:752–762.PubMedGoogle Scholar
  86. 86.
    Ren J, Jefferson L, Sowers JR. Influence of age on contractile response to INS-like growth factor 1 in ventricular myocytes from spontaneously hypertensive rats. Hypertension 1999;34:1215–1222.PubMedGoogle Scholar
  87. 87.
    Ren J, Samson WK, Sowers JR. INS-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999;31:2049–2061.PubMedGoogle Scholar
  88. 88.
    Ren J, Sowers JR, Walsh MF, et al. Reduced contractile response to INS and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol 2000;279:H1708–H1714.Google Scholar
  89. 89.
    Hemmings BA. Akt signaling: linking membrane events to life and death situations. Science 1997;275:628–630.PubMedGoogle Scholar
  90. 90.
    Somwar R, Srimitani S, Klip A. Temporal activation of p70 S6 kinase and Akt1 by INS: PI3-kinase-dependent and-independent mechanisms. Am J Physiol 1998;38:E618–E625.Google Scholar
  91. 91.
    Begum N, Ragolia L, Rienzie J, et al. Regulation of mitogen-activated protein kinase phosphatase-1 induction by INS in vascular smooth muscle cells. J Biol Chem 1998;273:25164–25170.PubMedGoogle Scholar
  92. 92.
    Kaliman P, Canicio J, Begum N, et al. INS-like growth factor II, phosphatidylinositol 3-kinase, nuclear factor-KB and inducible nitric oxide synthase define a common myogenic signaling pathway. J Biol Chem 1999;274:17,437–17,444.PubMedGoogle Scholar
  93. 93.
    Dinmeter S, Fleming I, Fiss I, Thoder B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601–605.Google Scholar
  94. 94.
    Luo Z, Fujio Y, Kureishi Y et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest 2000;106:493–499.PubMedGoogle Scholar
  95. 95.
    Hermann C, Assmus B, Urbich C, et al. INS-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:402–409.PubMedGoogle Scholar
  96. 96.
    Begum N, Song Y, Rienzie J, et al. Vascular smooth muscle cell growth and INS regulation of mitogen-activated protein kinase in hypertension. Am J Physiol 1998;275:C42–C49.PubMedGoogle Scholar
  97. 97.
    Villoso LA, Folli F, Sun XJ, et al. Cross-talk between the INS and angiotensin signaling systems. Proc Natl Acad Sci USA 1996;93:12,490–12,495.Google Scholar
  98. 98.
    Isenovic E, Walsh MF, Muniyappa R, Bard M, Diglio CA, Sowers JR. Phosphatidylinositol 3-kinase may mediate isoproterenol-induced vascular relaxation, in part through nitric oxide production. Metabolism 2002;51:380–386.PubMedGoogle Scholar
  99. 99.
    Lee MR, Li L, Kitazawa T. cGMP causes Ca2+ desensitization in vascular smooth muscle cells by activating the myosin light chain phosphatase. J Biol Chem 1997;272:5063–5068.PubMedGoogle Scholar
  100. 100.
    Begum N, Duddy N, Sandu OA, et al. Regulation of myosin bound protein phosphatase by INS in vascular smooth muscle cells. Evaluation of the role of Rho kinase and PI3-kinase dependent signaling pathways. Mol Endocrinol 2000;14:1365–1376.PubMedGoogle Scholar
  101. 101.
    Surks HK, Mochizuki N, Kasai Y, et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase 1 alpha. Science 1999;286:1583–1587.PubMedGoogle Scholar
  102. 102.
    Sauzeau V, LeJeune H, Cario-Toumaniantz C, et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000;275:21,722–21,729.PubMedGoogle Scholar
  103. 103.
    Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273:245–248.PubMedGoogle Scholar
  104. 104.
    Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990–994.PubMedGoogle Scholar
  105. 105.
    Yamakawa T, Tanaka A, Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Hypertension 2000;35:313–318.PubMedGoogle Scholar
  106. 106.
    Kitazawa T, Eto M, Woodsome TP, Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem 2000;275:9897–9900.PubMedGoogle Scholar
  107. 107.
    Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-Kinase in vivo. J Cell Biol 1999;147:1023–1038.PubMedGoogle Scholar
  108. 108.
    Feng J, Ito M, Ichikawa K, et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999;274:37385–7390.PubMedGoogle Scholar
  109. 109.
    Chibalin AV, Kovalenko MV, Ryder JW, et al. INS-and glucose-induced phosphorylation of the Na(+), K(+)-adenosine triphosphatase alpha-subunits in rat skeletal muscle. Endocrinology 2001;42:3474–3482.Google Scholar
  110. 110.
    Sandu OA, Ito M, Begum N. Selected Contribution: INS utilizes NO/cGMP pathway to activate myosin phosphatase via Rho inhibition in vascular smooth muscle. J Appl Physiol 2001;91:1475–482.PubMedGoogle Scholar
  111. 111.
    Berk B, Duff J, Marrero M. Angiotensin II signal transduction in vascular smooth muscle. In: Sowers JR, (ed.). Endocrinology of the Vasculature. Totowa, New Jersey, Humana Press, 1996, pp. 187–204.Google Scholar
  112. 112.
    Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047–1052.PubMedGoogle Scholar
  113. 113.
    Kureishi Y, Kobayashi S, Amano M, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997;272:1257–12260.Google Scholar
  114. 114.
    Folli F, Kahn R, Hansen H, et al. Angiotensin II inhibits INS signaling in aortic smooth muscle cells at multiple levels. J Clin Invest 1997;100:2158–2169.PubMedGoogle Scholar
  115. 115.
    Clark E, King W, Brugge JS, et al. Integrin-mediated signals regulated by members of the Rho family of GTPases. J Cell Biol 1998;142:573–586.PubMedGoogle Scholar
  116. 116.
    Sandu O, Ragolia L, Begum N. Diabetes in the Goto-Kakizaki rat is accompanied by impaired INS-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes 2000;49:2178–2189.PubMedGoogle Scholar
  117. 117.
    Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597–H1602.PubMedGoogle Scholar
  118. 118.
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317(7160):703–713.Google Scholar
  119. 119.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755–1762.PubMedGoogle Scholar
  120. 120.
    Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340(9):677–684.PubMedGoogle Scholar
  121. 121.
    Curb JD, Pressel SL, Cutler J A, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276(23):1886–1892.PubMedGoogle Scholar
  122. 122.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903–1913.PubMedGoogle Scholar
  123. 123.
    Arauz-Pacheco C, Parrott MA, Raskin P, American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S80–S82.PubMedGoogle Scholar
  124. 124.
    Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781–788.PubMedGoogle Scholar
  125. 125.
    Chobanian AV, Bakris GL, Black HR, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560–2572.PubMedGoogle Scholar
  126. 126.
    Sacks FM, Svetkey LP, Vollmer WM, et al., DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344(1):3–10.PubMedGoogle Scholar
  127. 127.
    Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health. Obes Res 1998;6(Suppl 2):51S–209S.Google Scholar
  128. 128.
    McFarlane SI, Shin JJ, Rundek T, Bigger JT. Prevention of type 2 diabetes. Curr Diab Rep 2003;3:235–241.PubMedGoogle Scholar
  129. 129.
    Eriksson KF, Lindgarde F. Prevention of type 2 (non-INS-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34:891–898.PubMedGoogle Scholar
  130. 130.
    Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS, Jr. Physical activity and reduced occurrence of non-INS-dependent diabetes mellitus. N Engl J Med 1991;325:147–152.PubMedGoogle Scholar
  131. 131.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–1350.PubMedGoogle Scholar
  132. 132.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.PubMedGoogle Scholar
  133. 133.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–2997.Google Scholar
  134. 134.
    Barzilay JI, Jones CL, Davis BR, et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001;24:654–658.PubMedGoogle Scholar
  135. 135.
    McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718–723.PubMedGoogle Scholar
  136. 136.
    McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91(12A):30H–37H.PubMedGoogle Scholar
  137. 137.
    Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT 1 receptor and NADPH oxidase. Hypertension 2003;42(2):206–212.PubMedGoogle Scholar
  138. 138.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;22;355(9200):253–259.Google Scholar
  139. 139.
    Lindholm LH, Ibsen H, Dahlof B, et al., LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):1004–1010.PubMedGoogle Scholar
  140. 140.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–2031.PubMedGoogle Scholar
  141. 141.
    Bakris GL, Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what’s the evidence. J Clin Hypertens (Greenwich) 2002;4(6):420–423.Google Scholar
  142. 142.
    Brenner BM, Cooper ME, de Zeeuw D, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861–869.PubMedGoogle Scholar
  143. 143.
    Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–878.PubMedGoogle Scholar
  144. 144.
    Lewis EJ, Hunsicker LG, Clarke WR, et al., Collaborative Study Group. effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 2001;345(12):851–860.PubMedGoogle Scholar
  145. 145.
    Viberti G, Wheeldon NM, Micro Albuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106(6):672–678.PubMedGoogle Scholar
  146. 146.
    Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-INS dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440–1444.PubMedGoogle Scholar
  147. 147.
    Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347(16):1256–1261.PubMedGoogle Scholar
  148. 148.
    Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: arandomized trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001;15(12):863–867.PubMedGoogle Scholar
  149. 149.
    Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? Arch Intern Med 2003;27;163(2):240–241.PubMedGoogle Scholar
  150. 150.
    Kirpichnikov D, McFarlane SI, Sowers JR. Heart failure in diabetic patients: utility of beta-blockade. J Card Fail 2003;9(4):333–344.PubMedGoogle Scholar
  151. 151.
    Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on INS sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14(4):489–494.PubMedGoogle Scholar
  152. 152.
    Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-INS-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126(12):955–959.PubMedGoogle Scholar
  153. 153.
    Intensive blood-glucose control with sulphonylureas or INS compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–853.Google Scholar
  154. 154.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.Google Scholar
  155. 155.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98(23):2513–2519.PubMedGoogle Scholar
  156. 156.
    McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451–1458.PubMedGoogle Scholar
  157. 157.
    Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001;24(2):197–201.PubMedGoogle Scholar

Copyright information

© Humama Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Samy I. McFarlane
    • 1
  • Amal F. Farag
    • 2
  • David Gardner
    • 3
  • James R. Sowers
    • 4
  1. 1.Department of MedicineState University of New York Health Science Center at Brooklyn Kings, Country Hospital CenterBrooklyn
  2. 2.Division of EndocrinologyNew York Harbor Veterans Administration CenterBrooklyn
  3. 3.Division of EndocrinologyUniversity of MissouriColumbia
  4. 4.Department of Cardiovascular MedicineUniversity of MissouriColumbia

Personalised recommendations